GET DAILY SIGNALSApyx Medical (APYX) Reports +9% Revenue Growth in Q3 2026 With Narrower Loss
Key Takeaways
- Apyx Medical reported third quarter 2026 revenue of $14.0 million, up 9% year over year and above the consensus estimate of roughly $13.3 million.
- The company posted a net loss of $0.04 per share, narrower than the $0.07 loss analysts had expected and an improvement from the $0.05 loss in the prior-year quarter.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) swung to a positive $0.4 million from a $0.1 million loss a year earlier, with management noting positive trailing 12-month EBITDA.
- Surgical Aesthetics revenue grew 17% to $13.0 million, while the smaller OEM (original equipment manufacturer) segment declined 41.5% to $1.1 million.
- Full-year 2026 revenue guidance was reaffirmed at $59 million to $60 million, and operating expense guidance was tightened to $41 million to $42.5 million.
Why These Results Matter Now
Apyx Medical’s third quarter 2026 results arrived at a pivotal moment for the surgical aesthetics company. The business is in the early stages of commercializing its AYON Body Contouring System and the newly launched power liposuction handpiece, which management estimates addresses the needs of roughly 70% of plastic surgeons. I’m watching this closely to see whether these newer products can sustain revenue momentum as the company laps the initial AYON launch from a year ago. At the same time, the company has been focused on cost discipline and a path toward profitability, making the improvement in adjusted EBITDA and the narrower net loss a central theme. The report also offers a window into how broader aesthetic-industry trends, including demand linked to GLP-1 weight-loss medications, are translating into actual sales. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Numbers
For the third quarter ended September 30, 2026, Apyx Medical reported total revenue of $14.0 million, a 9% increase from $12.9 million in the same period a year earlier and above the consensus estimate of roughly $13.3 million. Net loss attributable to shareholders narrowed to $1.8 million, or $0.04 per share, compared with a loss of $2.0 million, or $0.05 per share, in the prior-year quarter. This beat the consensus expectation of a $0.07 per share loss.
Surgical Aesthetics revenue rose 17% to $13.0 million, driven by AYON sales in the United States and higher international Renuvion generator sales. Domestic revenue increased 4% to $9.7 million, while international revenue grew 22% to $4.3 million. The OEM segment declined 41.5% to $1.1 million as the company continues to de-prioritize that business. Gross margin was 64.2%, slightly below the 64.4% recorded a year ago, reflecting geographic and product mix. Adjusted EBITDA improved to a positive $0.4 million from a $0.1 million loss, and cash and cash equivalents totaled $25.8 million at quarter-end.
How the Market Is Responding
Sentiment around Apyx Medical’s third quarter report has been shaped by a tension between an improving bottom line and decelerating top-line growth. The narrower-than-expected loss, the swing to positive adjusted EBITDA, and tightened expense guidance were viewed favorably. However, revenue growth has stepped down from higher double-digit rates in recent quarters to 9% in the third quarter, partly because the company is now lapping its initial AYON launch. Weaker domestic sales of standalone generators and lower global single-use handpiece sales offset some of the AYON momentum. The reaffirmed full-year revenue range implies a roughly flat fourth-quarter comparison, which has kept some investors cautious despite the improved profitability metrics.
What to Watch Going Forward
Looking ahead, investors should watch several factors that could shape Apyx Medical’s trajectory. The first is the pace of AYON adoption and the rollout of its power liposuction handpiece. Management confirmed that all initial orders for the handpiece were filled by the end of the third quarter, and about 25% of AYON sales now come from new customers, up from roughly 20% earlier in the year.
A second area to monitor is international expansion. AYON is currently sold only in the United States, and management is pursuing regulatory registrations in Europe, the Middle East, and Latin American markets, including Brazil, Colombia, and Mexico. Timing and success of these approvals could meaningfully broaden the addressable market.
Finally, investors should track cash management and the path to sustained profitability. Cash and equivalents stood at $25.8 million, with average quarterly cash burn of about $2 million, while long-term debt and associated interest expense continue to weigh on GAAP results. Margin trends, expense discipline, and any commentary on demand from patients using GLP-1 weight-loss medications will remain important signals in the quarters ahead. From what I see, Tickeron’s AI Trend Prediction Engine offers useful context on how similar names have performed after product launches.
Enhancing Research With AI Tools
One tool I find particularly useful for this kind of analysis is Tickeron’s AI Screener. It allows me to quickly compare APYX with peers in the medical device space and spot emerging trends. I’ve used it to filter for similar companies showing improving EBITDA trends, which provides additional perspective on the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
APYX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for APYX turned positive on October 12, 2026. Looking at past instances where APYX's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on APYX as a result. In 86 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
APYX moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where APYX advanced for three days, in 196 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
APYX broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for APYX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.088) is normal, around the industry mean (4.115). P/E Ratio (-15.300) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.390) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.196) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. APYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of a variety of electrosurgical medical products
Industry MedicalNursingServices
Advertisement